CG Oncology Inc. CGON 深 滬
等待開盤 10-02 09:30:00 美东时间
39.46
-0.820
-2.04%
華盛通- 最 高40.65
- 今 開40.03
- 成交量 112.79万股
- 最 低 39.33
- 昨 收 40.28
- 總市值 30.08亿
- 52周最高 40.65
- 市盈率 靜 --
- 換手率 1.48%
- 52周最低 14.80
- 委 比 71.96%
- 總股本 7622.53万
- 歷史最高 50.23
- 量 比 1.90
- 振 幅 3.28%
- 歷史最低 14.80
- 每 手 1
- 風險率 4.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $47
JP Morgan analyst Brian Cheng maintains CG Oncology (NASDAQ: CGON) with a Overweight and raises the price target from $41 to $47.
09-26 19:46
Goldman Sachs Remains a Buy on CG Oncology, Inc. (CGON)
Goldman Sachs analyst Corinne Johnson maintained a Buy rating on CG Oncology, I...
09-22 19:05
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $79
Morgan Stanley analyst Jeffrey Hung maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $56 to $79.
09-18 02:00
美股大行评级 | Bernstein：首予Bullish"与大市齐平"评级，目标价60美元
今日重点评级关注：TD Cowen：上调加拿大鹅评级至"买入"，目标价从16美元升至18美元；Vertical Research：上调波音评级至"买入"，目标价从242美元升至270美元
09-09 09:58
CG Oncology Stock Signals Bullish Momentum Ahead
CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track...
09-08 21:08
美股大行评级 | 潜在涨幅65.5%！花旗上调Braze目标价至52美元，维持"买入"评级
今日重点评级关注：花旗：维持Braze"买入"评级，目标价从50美元升至52美元；花旗：维持Docusign"买入"评级，目标价从115美元升至120美元
09-08 10:23
CG Oncology Announced Updated Data On BOND-003 Cohort C Showing 12 Additional Patients With High Risk Non-muscle Invasive Bladder Cancer Were In Complete Response At 24 Months, With Complete Response Rate Of 41.8%
Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG)
09-05 19:04
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
CG Oncology announced updated data from its Phase 3 BOND-003 Cohort C study, showing cretostimogene monotherapy achieved a 24-month complete response rate of 41.8% in high-risk non-muscle invasive bladder cancer (NMIBC) patients unresponsive to BCG. The study also revealed that 90% of 12-month responders remained disease-free at 24 months with no Grade 3 or higher treatment-related adverse events. These results highlight cretostimogene's durabili...
09-05 11:00
